Short‐term clinical outcomes and safety of the SpineJack implant system for the treatment of pathological vertebral compression fractures in cancer patients: A retrospective analysis
Pain Practice · 2025
DOI: 10.1111/papr.70020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Practice, 2025. Verfasst von Jason Parmar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Fractures, Compression, Spinal Fractures, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The SpineJack implant system is an FDA‐approved treatment modality for vertebral compression fractures (VCFs) with reported clinical efficacy comparable to the gold‐standard balloon kyphoplasty. Specifically, there is insufficient literature regarding the treatment and safety outcomes of the SpineJack when analyzing a specific subset of patients such as the cancer population.
Methods
This is an institutional‐level retrospective study at a cancer center on the SpineJack implant consisting of 67 cancer patients (mean age 64 ± 13 years) undergoing a total of 94 SpineJack implantations inserted at 15 thoracolumbar vertebral levels for the treatment of pathologic vertebral compression fractures. The primary outcome of the study was the change in pain score based on the Numeric Rating Scale (NRS) and the secondary outcome was the change in opioid requirement based on morphine milligram equivalents (MME). The average follow‐up period was 2 weeks.
Results
Post‐procedure, a statistically significant decrease in pain severity was observed, with the mean pain score improving from 7.72 ± 2.29 points to 3.45 ± 2.55 points ( p ‐value < 0.0001). Additionally, a reduction in opioid requirement was noted, with a decrease in MME from 66.42 ± 92.66 mg preoperatively to 43.1 ± 60.78 mg ( p ‐value < 0.0001) postoperatively. There was a 1.5% ( N = 1) incidence of adjacent level fracture (ALF) reported over an average of 2‐week follow‐up. The most common intraoperative complication reported was cement extravasation.
Conclusion
Overall, treatment of cancer patients with pathologic fractures using the SpineJack procedure resulted in remarkably decreased pain scores, overall decreased MME requirements, a significantly low incidence of ALF (s), and minor intraoperative complications without long‐term consequences. The SpineJack procedure is a clinically effective, low‐risk treatment option for cancer patients with symptomatic, pathologic VCFs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas, USA.
- Department of Physical Medicine and Rehabilitation, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
ORCID-Profile: Jason Parmar, Aila Malik, Saba Javed
Zitieren
APA
Parmar, J., Malik, A., Zemmedhun, G., & Javed, S. (2025). Short‐term clinical outcomes and safety of the SpineJack implant system for the treatment of pathological vertebral compression fractures in cancer patients: A retrospective analysis. Pain Practice. https://doi.org/10.1111/papr.70020
Vancouver
Parmar J, Malik A, Zemmedhun G, Javed S. Short‐term clinical outcomes and safety of the SpineJack implant system for the treatment of pathological vertebral compression fractures in cancer patients: A retrospective analysis. Pain Practice. 2025. doi:10.1111/papr.70020
BibTeX
@article{Parmar2025,
author = {Parmar, Jason and Malik, Aila and Zemmedhun, Gelilla and Javed, Saba},
title = {Short‐term clinical outcomes and safety of the SpineJack implant system for the treatment of pathological vertebral compression fractures in cancer patients: A retrospective analysis},
journal = {Pain Practice},
year = {2025},
doi = {10.1111/papr.70020}
}
EUVIMED